Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: kowalski k. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G, Bentley D, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Brink A, Djebli N, Mercier F, Buchheit V, Phipps A. Meneses-Lorente G, et al. Among authors: kowalski k. Invest New Drugs. 2021 Jun;39(3):803-811. doi: 10.1007/s10637-020-01047-5. Epub 2021 Jan 18. Invest New Drugs. 2021. PMID: 33462752 Free PMC article. Clinical Trial.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G, Fowler S, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Mercier F, Ullah M, Umehara K, Brink A, Buchheit V, Zwanziger E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: kowalski k. Invest New Drugs. 2022 Feb;40(1):68-80. doi: 10.1007/s10637-021-01156-9. Epub 2021 Aug 21. Invest New Drugs. 2022. PMID: 34417912 Free PMC article.
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Meneses-Lorente G, Guerini E, Mercier F, Parrott N, Kowalski K, Chow-Maneval E, Buchheit V, Bergthold G, Fox E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: kowalski k. Cancer Chemother Pharmacol. 2023 Mar;91(3):239-246. doi: 10.1007/s00280-023-04510-1. Epub 2023 Mar 8. Cancer Chemother Pharmacol. 2023. PMID: 36884068 Free PMC article.
Association between physical measures of spinopelvic alignment and physical functioning with patient reported outcome measures (PROMs) after total hip arthroplasty: Protocol for systematic review and meta-analysis.
Vatandoost S, Kowalski K, Lanting B, Ng KCG, Soltanabadi S, Rushton A. Vatandoost S, et al. Among authors: kowalski k. PLoS One. 2024 May 24;19(5):e0304382. doi: 10.1371/journal.pone.0304382. eCollection 2024. PLoS One. 2024. PMID: 38787884 Free PMC article.
Covariate modeling in pharmacometrics: General points for consideration.
Sanghavi K, Ribbing J, Rogers JA, Ahmed MA, Karlsson MO, Holford N, Chasseloup E, Ahamadi M, Kowalski KG, Cole S, Kerwash E, Wade JR, Liu C, Wang Y, Trame MN, Zhu H, Wilkins JJ; ISoP Standards & Best Practices Committee. Sanghavi K, et al. Among authors: kowalski kg. CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):710-728. doi: 10.1002/psp4.13115. Epub 2024 Apr 2. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38566433 Free PMC article. Review.
623 results